Complications of Brentuximab Therapy in Patients with Hodgkin’s Lymphoma and Concurrent Autoimmune Pathology—A Case Series
Authors:
Open Access
- 20 May 2024
- journal article
- case report
- Published by MDPI AG in Hematology Reports
- Vol. 16 (2) , 299-307
Abstract
Background: Brentuximab Vedotin (BV) has revolutionized the treatment landscape for Hodgkin’s lymphoma, yet its effects on pre-existing autoimmune disorders remain elusive. Methods: Here, we present four cases of patients with concurrent autoimmune conditions—Crohn’s disease, vitiligo, type I diabetes, and minimal change disease—undergoing BV therapy for Hodgkin’s lymphoma. The patients were treated with A-AVD instead of ABVD due to advanced-stage disease with high IPI scores. Results: Our findings reveal the surprising and complex interplay between BV exposure and autoimmune manifestations, highlighting the need for multidisciplinary collaboration in patient management. Notably, the exacerbation of autoimmune symptoms was observed in the first three cases where T-cell-mediated autoimmunity predominated. Additionally, BV exposure precipitated autoimmune thrombocytopenia in the vitiligo patient, underscoring the profound disruptions in immune regulation. Conversely, in the minimal change disease case, a disease characterized by a blend of B- and T-cell-mediated immunity, the outcome was favorable. Conclusions: This paper underscores the critical importance of vigilance toward autoimmune flare-ups induced by BV in patients with concurrent autoimmune conditions, offering insights for tailored patient care.Keywords
This publication has 27 references indexed in Scilit:
- Minimal Change Disease: More Than a Podocytopathy?Kidney International Reports, 2022
- The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaAnnals of Oncology, 2021
- Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factorsClinical and Experimental Immunology, 2021
- Crohn’s diseaseNature Reviews Disease Primers, 2020
- History of autoimmune conditions and lymphoma prognosisBlood Cancer Journal, 2018
- Diagnostic, prognostic and therapeutic role of CD30 in lymphomaExpert Review of Hematology, 2016
- Updated assessment of the prevalence, spectrum and case definition of autoimmune diseaseAutoimmunity Reviews, 2012
- Targeting CD30/CD30L in Oncology and Autoimmune and Inflammatory Diseases2009
- Unravelling the pathogenesis of myasthenia gravisNature Reviews Immunology, 2002
- Regulation of CD30 Antigen Expression and Its Potential Significance for Human DiseaseThe American Journal of Pathology, 2000